《医学前沿（英文）》 2011年 第5卷 第4期 页码 348-355 doi: 10.1007/s11684-011-0150-x
《医学前沿（英文）》 2014年 第8卷 第2期 页码 190-200 doi: 10.1007/s11684-014-0323-5
Over the past few years, several new achievements have been made from stem cell studies, many of which have moved up from preclinical stages to early, or from early to middle or late, stages thanks to relatively safe profile and preliminary evidence of effectiveness. Moreover, some stem cell-based products have been approved for marketing by different national regulatory authorities. However, many critical issues associated mainly with incomplete understanding of stem cell biology and the relevant risk factors, and lack of effective regulations still exist and need to be urgently addressed, especially in countries where establishment of appropriate regulatory system just commenced. More relevantly, the stem cell regulatory sciences need to be established or improved to more effectively evaluate quality, safety and efficacy of stem cell products, and for building up the appropriate regulatory framework. In this review, we summarize some new achievements in stem cell studies, especially the preclinical and clinical studies, the existing regulations, and the associated challenges, and we then propose some considerations for improving stem cell regulatory sciences with a goal of promoting the steadfast growth of the well-regulated stem cell therapies abreast of evolvement of stem cell sciences and technologies.
《医学前沿（英文）》 2011年 第5卷 第1期 页码 26-32 doi: 10.1007/s11684-011-0107-0
Liver transplantation is the only life-saving procedure for patients with end-stage liver disease. However, its potential benefits are hampered by many disadvantages, such as the relative shortage of donors, operative risks, and high costs. These issues have prompted the search for new alternative therapies for irreversible liver disease. Stem cell therapy, with the ability for self-renewal and potential for multilineage differentiation, is a promising alternative approach. Several studies have demonstrated that transplantation of hepatic stem/progenitor cells or hepatocyte-like cells derived from multipotent stem cells leads to donor cell-mediated repopulation of the liver and improved survival rates in experimental models of liver disease. However, a registered clinical application based on stem cell technology will take at least an additional 5 to 10 years because of some limitations; e.g. the lack of suitable cell sources and risk of teratoma formation. This review summarizes the general understanding of the therapeutic potentials of stem cells in liver disease, including the sources, mechanisms, and delivery methods of hepatic stem cells in liver regeneration, and discusses some challenges for their therapeutic application.
《医学前沿（英文）》 2011年 第5卷 第1期 页码 40-44 doi: 10.1007/s11684-011-0108-z
Adult stem cells are responsible for homeostasis and repair of many tissues. Endogenous adult stem cells reside in certain regions of organs, known as the stem cell niche, which is recognized to have an important role in regulating tissue maintenance and repair. In wound healing and tissue repair, stem cells are mobilized and recruited to the site of wound, and participate in the repair process. Many regulatory factors are involved in the stem cell-based repair process, including stem cell niches and endogenous wound electric fields, which are present at wound tissues and proved to be important in guiding wound healing. Here we briefly review the role of stem cell niches and endogenous electric fields in tissue repair, and hypothesize that endogenous electric fields become part of stem cell niche in the wound site.
《医学前沿（英文）》 2014年 第8卷 第4期 页码 433-444 doi: 10.1007/s11684-014-0336-0
Stem cells are capable of self-renewal and differentiation, and the processes regulating these events are among the most comprehensively investigated topics in life sciences. In particular, the molecular mechanisms of the self-renewal, proliferation, and differentiation of stem cells have been extensively examined. Multi-omics integrative analysis, such as transcriptomics combined with proteomics, is one of the most promising approaches to the systemic investigation of stem cell biology. We reviewed the available information on stem cells by examining published results using transcriptomic and proteomic characterization of the different stem cell processes. Comprehensive understanding of these important processes can only be achieved using a systemic methodology, and employing such method will strengthen the study on stem cell biology and promote the clinical applications of stem cells.
《医学前沿（英文）》 2013年 第7卷 第3期 页码 306-315 doi: 10.1007/s11684-013-0279-x
Allogeneic hematopoietic stem cell transplantation (HSCT) is one of the most effective options for hematological malignancies, and human leukocyte antigen-partially matched related donors (PMRDs) are a valuable option for HSCT. Several protocols (with or without ex vivo T-cell depletion (TCD)) have been established worldwide. TCD including CD34+positive selection and CD3/CD19 depletion has successfully overcome the human leukocyte antigen disparity. However, TCD is associated with prolonged immune deficiencies, increased risks of infectious complications, and high transplantation-related mortality. PMRD HSCT without ex vivo TCD is well developed, and numerous patients have benefitted from it. Here, we review the literature on PMRD HSCT.
《医学前沿（英文）》 2022年 第16卷 第2期 页码 227-239 doi: 10.1007/s11684-021-0896-8
Panpan Zhang, Feng Liu
《医学前沿（英文）》 2011年 第5卷 第3期 页码 239-247 doi: 10.1007/s11684-011-0123-0
《医学前沿（英文）》 2015年 第9卷 第4期 页码 412-420 doi: 10.1007/s11684-015-0423-x
Genetic mutations are considered to drive the development of acute myeloid leukemia (AML). With the rapid progress in sequencing technologies, many newly reported genes that are recurrently mutated in AML have been found to govern the initiation and relapse of AML. These findings suggest the need to distinguish the driver mutations, especially the most primitive single mutation, from the subsequent passenger mutations. Recent research on DNA methyltransferase 3A (DNMT3A) mutations provides the first proof-of-principle investigation on the identification of preleukemic stem cells (pre-LSCs) in AML patients. Although DNMT3A mutations alone may only transform hematopoietic stem cells into pre-LSCs without causing the full-blown leukemia, the function of this driver mutation appear to persist from AML initiation up to relapse. Therefore, identifying and targeting preleukemic mutations, such as DNMT3A mutations, in AML is a promising strategy for treatment and reduction of relapse risk.
Chuanfeng Wu, Cynthia E. Dunbar
《医学前沿（英文）》 2011年 第5卷 第4期 页码 356-371 doi: 10.1007/s11684-011-0159-1
GE Jian, LIU Jingbo
《医学前沿（英文）》 2007年 第1卷 第1期 页码 6-10 doi: 10.1007/s11684-007-0002-x
Qiming Zhai, Zhiwei Dong, Wei Wang, Bei Li, Yan Jin
《医学前沿（英文）》 2019年 第13卷 第2期 页码 152-159 doi: 10.1007/s11684-018-0628-x
《医学前沿（英文）》 2022年 第16卷 第6期 页码 827-858 doi: 10.1007/s11684-022-0948-8
《医学前沿（英文）》 2018年 第12卷 第2期 页码 224-228 doi: 10.1007/s11684-017-0538-3
Bronchiolitis obliterans syndrome (BOS) after hematopoietic stem cell transplantation (HSCT) is a major cause of morbidity and mortality with limited treatment options. Lung transplantation (LTX) has been rarely reported as a treatment option for selected HSCT recipients with this problem. In the present study, we reported six patients who underwent LTX due to BOS after HSCT (two females, four males) from January 2012 to December 2014 in our center. The median time from HSCT to diagnosis of BOS was 2.5 years (ranging from 1 to 5 years). At a median time of 4 years (ranging from 2 to 5 years) after diagnosis of BOS, four patients received bilateral sequential LTX, and two patients received single LTX. One of the recipients suffered from mild acute rejection after LTX, another suffered from primary lung graft dysfunction on post-operation day 2, and three experienced fungal infections. The median time for follow-up after LTX was 19.5 months (ranging from 12 to 39 months). At present, all patients are alive with good functional capacity and no relapse of BOS and hematologic malignancy conditions. Patients who received bilateral LTX have better pulmonary functions than patients who received single LTX.
《医学前沿（英文）》 2022年 第16卷 第6期 页码 957-968 doi: 10.1007/s11684-021-0910-1
标题 作者 时间 类型 操作
Advancement of human leukocyte antigen-partially matched related hematopoietic stem cell transplantation
Cannabidiol prevents depressive-like behaviors through the modulation of neural stem cell differentiation
Mutant DNA methylation regulators endow hematopoietic stem cells with the preleukemic stem cell property
Stem cell gene therapy: the risks of insertional mutagenesis and approaches to minimize genotoxicity
Chuanfeng Wu, Cynthia E. Dunbar
Dental stem cell and dental tissue regeneration
Qiming Zhai, Zhiwei Dong, Wei Wang, Bei Li, Yan Jin
Cell therapy for the treatment of reproductive diseases and infertility: an overview from the mechanism
Lung transplantation for bronchiolitis obliterans syndrome after allogenic hematopoietic stem cell transplantation